1. Periocular injection of candesartan-PLGA microparticles inhibits laser-induced experimental choroidal neovascularization
- Author
-
Okuda Y, Fukumoto M, Horie T, Oku H, Takai S, Nakanishi T, Matsuzaki K, Tsujimoto H, and Ikeda T
- Subjects
age-related macular degeneration ,choroidal neovascularization ,renin-angiotensin system ,candesartan ,macrophage ,monocyte chemotactic protein 1 ,poly(lactic-co-glycolic acid) ,Ophthalmology ,RE1-994 - Abstract
Yoshitaka Okuda,1 Masanori Fukumoto,1 Taeko Horie,1 Hidehiro Oku,1 Shinji Takai,2 Toyofumi Nakanishi,3 Kaori Matsuzaki,4 Hiroyuki Tsujimoto,4 Tsunehiko Ikeda1 1Department of Ophthalmology, Osaka Medical College, Osaka, Japan; 2Department of Innovative Medicine, Graduate School of Medicine, Osaka Medical College, Osaka, Japan; 3Department of Clinical and Laboratory Medicine, Osaka Medical College, Osaka, Japan; 4Research and Development Division, Hosokawa Micron Corporation, Osaka, Japan Purpose: Microparticle technology enables local administration of medication. The purpose of this study was to examine the inhibitory effect of locally administered candesartan (CAN)-encapsulated microparticles on experimental choroidal neovascularization (CNV). Methods: Laser photocoagulation was used to induce CNV in Brown Norway rats. The rats were pretreated with subconjunctival injections of CAN (5.0 mg/eye) or phosphate buffer saline for 3 days before photocoagulation. The volume of CNV was evaluated 7 days after laser injury using the lectin staining technique. The infiltration of macrophages within the CNV lesion was determined using immunofluorescent staining with an anti-CD68 antibody. mRNA levels of MCP-1, IL1-β and VEGF in the retinal pigment epithelium/choroid complex were determined using quantitative PCR (q-PCR). Results: CNV volume was significantly suppressed by the treatment with CAN compared with that in vehicle-treated eyes (P
- Published
- 2018